ApoE genotype influences on efficacy and safety of thrombolytic treatment for ischemic stroke;Influencia del genotipo ApoE sobre la eficacia y seguridad del tratamiento trombolítico en el ictus isquémico

Neurologia

Volumn 21, Issue 4, 2006, Pages 176-180

  Fernandez Cadenas I ^a   Alvarez Sabin J ^a   Molina, C A ^a   Ribo M ^a   Rosell, A ^a   Penalba, A ^a   Ortega, L ^a   Montaner, Joan ^a,b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ApoE; Hemorrhagic transformation; Recanalization; rt PA; Stroke

Indexed keywords

ALTEPLASE; APOLIPOPROTEIN E;

ARTICLE; CEREBROVASCULAR ACCIDENT; COMPUTER ASSISTED TOMOGRAPHY; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; FIBRINOLYTIC THERAPY; GENOTYPE; HUMAN; RECANALIZATION; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; APOLIPOPROTEINS E; CEREBROVASCULAR ACCIDENT; FEMALE; FIBRINOLYTIC AGENTS; GENOTYPE; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33745162254     PISSN: 02134853     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Dávalos A. Thrombolytic treatment in acute brain infarction. Neurologia 2004;19:143-5.
2. NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997;28:2109-18.
3. Wardlaw JM, Warlow CP, Counsell C. Systematic review of evidence on thrombolytic therapy for acute ischaemic stroke. Lancet 1997;350:607-14.
4. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 1995;333:1242-7.
5. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC Jr, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet 1994;7:180-4.
6. Talbot C, Lendon C, Craddock N, Shears S, Morris JC, Goate A. Protection against Alzheimer's disease with apoE epsilon 2. Lancet 1994;343:1432-3.
7. Broderick J, Lu M, Jackson C, Pancioli A, Tilley BC, Fagan SC, et al. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001;49:736-44.
8. Clark JF, Huri DA, Carrozzella J, Jauch EC, Mehta P, Heaton D, et al. Isoforms of apolipoprotein E can modulate tPA-induced clot lysis in vitro. Front Biosci 2002;1:163-8.
9. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE 3rd. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
10. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA 1995;274:1017-25.
11. Pessin M, del Zoppo G, Estol C. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol 1990;13:271-89.
12. Burgin WS, Malkoff M, Felberg RA, Demchuk AM, Christou I, Grotta JC, et al. Transcranial doppler ultrasound criteria for recanalization after thrombolysis for middle cerebral artery stroke. Stroke 2000;31:1128-32.
13. Kidwell CS, Saver JL, Villablanca JP, Duckwiler G, Fredieu A, Gough K, et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: an emerging application. Stroke 2002;33:95-8.
14. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003;107:598-603.
15. Ribo M, Montaner J, Molina CA, Arenillas JF, Santamarina E, Alvarez-Sabin J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004;91:1146-51.
16. Greenberg SM, Vonsattel JP, Segal AZ, Chiu RI, Clatworthy AE, Liao A, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998;50:961-5.
17. Nicoll JA, Burnett C, Love S, Graham DI, Dewar D, Ironside JW, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy. Ann Neurol 1997;41:716-21.
18. Greenberg SM, Rebeck GW, Vonsattel JP, Gomez-Isla T, Hyman BT. Apolipoprotein E epsilon 4 and cerebral hemorrhage associated with amyloid angiopathy. Ann Neurol 1995;38:254-9.
19. Greenberg SM, Briggs ME, Hyman BT, Kokoris GJ, Takis C, Kanter DS, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996;27:1333-7.
20. McCarron MO, Nicoll JA. High frequency of apolipoprotein E epsilon 2 allele is specific for patients with cerebral amyloid angiopathy-related haemorrhage. Neurosci Lett 1998;247:45-8.